Eli Lilly’s metabolic medicine takes the lead

The latest stories trending on MedCity News.

Editor's Pick

Top Story Eli Lilly's Metabolic Medicine Takes the Lead in the Race to Develop an Oral GLP-1 Drug The first Phase 3 results for Eli Lilly's daily pill orforglipron show statistically significant reductions in blood sugar and body weight in patients with type 2 diabetes. The pharmaceutical giant plans global regulatory submissions starting at the end of this year. Sponsored How To Make It Easier For Early Stage Life Science Companies to Grow Presented by Mercury and MedCity News A webinar on May 8th, sponsored by fintech business Mercury will explore how a banking platform approach could be a resource for the needs of entrepreneurs across biotech, diagnostics, and other life science companies. Sign up to learn more! Advanced Rate Extended! The Advanced Rate has been extended for MedCity INVEST and now ends Friday 4/18. Join us in Chicago, May 21-22, to hear from visionary healthcare leaders and connect with top investors. Final Call to Secure your ticket before prices do increase! Register Now to Save $300

Featured News

New Pregnancy App Launches to Support Mothers Through Birth and Beyond Trellis Health emerged from stealth and announced $1.8 million in pre-seed funding. The platform helps women easily access and understand their medical records so they can make better health decisions during pregnancy and throughout their lives. Peterson Center on Healthcare: 3 Policy Recommendations for Remote Health Technologies In a new report, the Peterson Center on Healthcare made policy recommendations on reimbursement, access and data collection for remote monitoring technologies. Health Plans Can Reduce Costs with a Focus on Rising Risk Healthcare organizations need to jump in with both feet when it comes to AI, as mitigating risk is quickly becoming an existential business issue. Machine learning has quickly gone from being a nice-to-have to a must-have. The Rise of Plant-Based Self-Medication and What Healthcare Must Do Next The self-medicating plant movement sits at the intersection of empowerment and misinformation. On one hand, it signals a growing desire for agency in personal health. On the other, it raises alarms about safety, oversight, and the risk of delayed care.

Video   Vaccine Makers Aren't Speaking Out Against RFK Jr. Earlier this year at the annual J.P. Morgan healthcare conference in San Francisco, Pfizer CEO Albert Bourla said his company would be at the vanguard fighting in favor of vaccines if Robert F. Kennedy Jr. took action against these treatments. Since then, the Texas measles outbreak has spread — and Kennedy has failed to encourage vaccines, instead stressing that they should be optional. Additionally, Peter Marks, the former head of the FDA's Center for Biologics Evaluation and Research, resigned this month, and he has gone on the record saying that vaccine misinformation reigns at Kennedy's HHS. MedCity News Senior Reporter Frank Vinluan reached out to Pfizer and other vaccine makers to comment on this issue, and the response has been radio silence — which is interesting considering Bourla's earlier comments.

Sponsored What Are the Best Medical Coding Outsourcing Companies? Presented by Global Healthcare Resource Outsourcing your medical coding can help ensure a healthy revenue cycle. Discover the best medical coding outsourcing companies and find the right one for you. Learn More

Resources

Pivot: Discussing the Impact of a Proposed HIPAA Security Update All healthcare entities storing or transferring patient health information needs to be aware of a proposed update to HIPAA tackling data encryption. Bryan Marlatt, chief regional officer at CyXcel, talks with us about the evolving threat landscape and what the proposed rule means for healthcare organizations. Listen now

MedCity News • PO Box 901 • New York, NY unsubscribe